{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:22:01Z","timestamp":1791649321537,"version":"4.3.4"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":327,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The aim was to study the clinical features of PMR\/GCA and clinical predictors of treatment response during a 40-week follow-up period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical data on 77 patients with newly diagnosed PMR\/GCA who were treated with oral glucocorticoids were gathered at baseline and during a 40-week follow-up period. A unilateral temporal artery biopsy (TAB) and 18F-fluorodeoxyglucose (18F-FDG) PET\/CT were undertaken at diagnosis. In total, each patient was seen on five occasions (i.e. baseline and weeks 4, 16, 28 and 40). Treatment response was assessed by considering clinical evaluations and results of inflammatory markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 77 patients [49 (63.6%) female; mean age 71.8 (8.0) years], 64 (83.1%) patients had pure PMR, 10 (13.0%) concomitant PMR and GCA, and 3 (3.9%) pure GCA. The patients reported that clinical symptoms, apart from scalp pain and duration of morning stiffness, improved significantly at week 4 and remained lower at week 40 compared with the relative frequencies at baseline. Besides, all components of physical examination showed significant improvement and remained lower at week 40 compared with the baseline. A complete response was seen in 68.7, 62.9, 44.1 and 33.3% of patients at weeks 4, 16, 28 and 40, respectively. Several clinical features, including female biological sex, younger age, fewer relapses and a lower level of baseline ESR, were significantly associated with a better treatment response. Treatment response during the follow-up period was independent of TAB results and fluorodeoxyglucose uptakes on 18F-FDG PET\/CT at diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Obtaining valid disease-specific outcome measures for evaluating treatment efficacy in PMR and GCA that can be applied universally is clearly an unmet clinical need.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, https:\/\/clinicaltrials.gov, NCT02985424.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rap\/rkab091","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T23:24:42Z","timestamp":1638314682000},"source":"Crossref","is-referenced-by-count":8,"title":["Clinical presentation and treatment response in patients with polymyalgia rheumatica and giant cell arteritis during a 40-week follow-up"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5329-1364","authenticated-orcid":false,"given":"Amir","family":"Emamifar","sequence":"first","affiliation":[{"name":"Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense"},{"name":"Diagnostic Center"},{"name":"Department of Rheumatology, Svendborg Hospital, OUH, Svendborg"},{"name":"OPEN, Odense Patient data Explorative Network, Odense University Hospital, Odense"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Hess","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Hospital of Southwest Jutland, Esbjerg"},{"name":"Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0426-4962","authenticated-orcid":false,"given":"Torkell","family":"Ellingsen","sequence":"additional","affiliation":[{"name":"Rheumatology Research Unit, Odense University Hospital and University of Southern Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6335-3303","authenticated-orcid":false,"given":"Oke","family":"Gerke","sequence":"additional","affiliation":[{"name":"Research Unit of Clinical Physiology and Nuclear Medicine, Department of Clinical Research, University of Southern Denmark"},{"name":"Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziba","family":"Ahangarani Farahani","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Syrak Hansen","sequence":"additional","affiliation":[{"name":"Diagnostic Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger Marie","family":"Jensen Hansen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Svendborg Hospital, OUH, Svendborg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Thye-R\u00f8nn","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense"},{"name":"Diagnostic Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"key":"2021121111263096400_rkab091-B1","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","article-title":"European League Against Rheumatism; American College of Rheumatology. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021121111263096400_rkab091-B2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1056\/NEJMra011913","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"347","author":"Salvarani","year":"2002","journal-title":"N Engl J Med"},{"key":"2021121111263096400_rkab091-B3","doi-asserted-by":"crossref","first-page":"20170198","DOI":"10.1259\/bjr.20170198","article-title":"18F-FDG PET\/CT in polymyalgia rheumatica\u2014a pictorial review","volume":"90","author":"Rehak","year":"2017","journal-title":"Br J Radiol"},{"key":"2021121111263096400_rkab091-B4","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s13075-015-0784-1","article-title":"Fatigue in chronic inflammation - a link to pain pathways","volume":"17","author":"Louati","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2021121111263096400_rkab091-B5","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1136\/bmj.314.7090.1329","article-title":"Polymyalgia rheumatica and temporal arteritis: diagnosis and management","volume":"314","author":"Swannell","year":"1997","journal-title":"BMJ"},{"key":"2021121111263096400_rkab091-B6","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/acr2.11163","article-title":"The utility of 18F-FDG PET\/CT in patients with clinical suspicion of polymyalgia rheumatica and giant cell arteritis: a prospective, observational, and cross-sectional study","volume":"2","author":"Emamifar","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2021121111263096400_rkab091-B7","doi-asserted-by":"crossref","first-page":"e7297","DOI":"10.1097\/MD.0000000000007297","article-title":"Polymyalgia rheumatica and giant cell arteritis\u2014three challenges\u2014consequences of the vasculitis process, osteoporosis, and malignancy: a prospective cohort study protocol","volume":"96","author":"Emamifar","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"2021121111263096400_rkab091-B8","author":"T\u00f8nder Hansen"},{"key":"2021121111263096400_rkab091-B9","author":"Open Patient data Explorative Network","year":"2019"},{"key":"2021121111263096400_rkab091-B10","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3899\/jrheum.110977","article-title":"Patient-reported outcomes in polymyalgia rheumatica","volume":"39","author":"Matteson","year":"2012","journal-title":"J Rheumatol"},{"key":"2021121111263096400_rkab091-B11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"2021121111263096400_rkab091-B12","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.3390\/jcm9123940","article-title":"Prevalence of newly diagnosed malignancies in patients with polymyalgia rheumatica and giant cell arteritis, comparison of 18F-FDG PET\/CT scan with chest X-ray and abdominal ultrasound: data from a 40 week prospective, exploratory, single centre study","volume":"9","author":"Emamifar","year":"2020","journal-title":"J Clin Med"},{"key":"2021121111263096400_rkab091-B13","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/rheumatology\/kex478","article-title":"In search of a diagnostic test for polymyalgia rheumatica: is positron emission tomography the answer?","volume":"57","author":"Clifford","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2021121111263096400_rkab091-B14","doi-asserted-by":"crossref","first-page":"e0126758","DOI":"10.1371\/journal.pone.0126758","article-title":"\u201cAn impediment to living life\u201d: why and how should we measure stiffness in polymyalgia rheumatica?","volume":"10","author":"Mackie","year":"2015","journal-title":"PLoS One"},{"key":"2021121111263096400_rkab091-B15","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/ard.2003.011379","article-title":"A disease activity score for polymyalgia rheumatica","volume":"63","author":"Leeb","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"2021121111263096400_rkab091-B16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41584-020-0458-5","article-title":"Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica","volume":"16","author":"Camellino","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2021121111263096400_rkab091-B17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41584-020-00551-5","article-title":"Reply to: What could a new disease activity score for polymyalgia rheumatica do better?","volume":"17","author":"Camellino","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"2021121111263096400_rkab091-B18","first-page":"130","article-title":"Management guidelines and outcome measures in polymyalgia rheumatica (PMR)","volume":"25","author":"Dasgupta","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"2021121111263096400_rkab091-B19","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/art.22777","article-title":"Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica","volume":"57","author":"Hutchings","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2021121111263096400_rkab091-B20","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.3899\/jrheum.161109","article-title":"The OMERACT core domain set for outcome measures for clinical trials in polymyalgia rheumatica","volume":"44","author":"Mackie","year":"2017","journal-title":"J Rheumatol"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkab091\/41278365\/rkab091.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/5\/3\/rkab091\/41724561\/rkab091.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/5\/3\/rkab091\/41724561\/rkab091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T07:04:04Z","timestamp":1699859044000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkab091\/6438023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,8,31]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkab091","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021]]},"published":{"date-parts":[[2021]]},"article-number":"rkab091"}}